Literature DB >> 20190798

DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer.

Frank A Sinicrope1.   

Abstract

Defective DNA mismatch repair (MMR) occurs in approximately 15% of sporadic colorectal cancers (CRCs). Multiple retrospective studies have shown that patients with MMR-deficient CRCs have a more favorable stage-adjusted prognosis compared with those who have MMR-proficient tumors. Evidence also indicates that patients with MMR-deficient colon cancers do not benefit from treatment with adjuvant 5-fluorouracil chemotherapy. Furthermore, recent studies, including a pooled analysis, have validated the prognostic and predictive impact of MMR status in patients with stage II and III colon cancer who were treated in adjuvant chemotherapy trials. Given these data, it can be recommended that MMR status be determined and used to inform clinical decision-making for adjuvant chemotherapy in patients with stage II colon cancer.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20190798      PMCID： PMC3767984          DOI： 10.1038/nrclinonc.2009.235

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  31 in total

Review 1.  Systematic review of microsatellite instability and colorectal cancer prognosis.

Authors:  S Popat; R Hubner; R S Houlston
Journal:  J Clin Oncol       Date:  2005-01-20       Impact factor: 44.544

2.  Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study.

Authors:  George P Kim; Linda H Colangelo; H Samuel Wieand; Soonmyung Paik; Ilan R Kirsch; Norman Wolmark; Carmen J Allegra
Journal:  J Clin Oncol       Date:  2007-01-16       Impact factor: 44.544

3.  Microsatellite instability and colorectal cancer prognosis.

Authors:  Piero Benatti; Roberta Gafà; Daniela Barana; Massimiliano Marino; Alessandra Scarselli; Monica Pedroni; Iva Maestri; Laura Guerzoni; Luca Roncucci; Mirco Menigatti; Barbara Roncari; Stefania Maffei; Giuseppina Rossi; Giovanni Ponti; Alessandra Santini; Lorena Losi; Carmela Di Gregorio; Cristina Oliani; Maurizio Ponz de Leon; Giovanni Lanza
Journal:  Clin Cancer Res       Date:  2005-12-01       Impact factor: 12.531

4.  Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer.

Authors:  C Lamberti; S Lundin; M Bogdanow; C Pagenstecher; N Friedrichs; R Büttner; T Sauerbruch
Journal:  Int J Colorectal Dis       Date:  2006-05-25       Impact factor: 2.571

5.  Mismatch repair proficiency and in vitro response to 5-fluorouracil.

Authors:  J M Carethers; D P Chauhan; D Fink; S Nebel; R S Bresalier; S B Howell; C R Boland
Journal:  Gastroenterology       Date:  1999-07       Impact factor: 22.682

6.  Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients.

Authors:  Frank A Sinicrope; Rafaela L Rego; Kevin C Halling; Nathan Foster; Daniel J Sargent; Betsy La Plant; Amy J French; John A Laurie; Richard M Goldberg; Stephen N Thibodeau; Thomas E Witzig
Journal:  Gastroenterology       Date:  2006-09       Impact factor: 22.682

7.  CpG island methylator phenotype in colorectal cancer.

Authors:  M Toyota; N Ahuja; M Ohe-Toyota; J G Herman; S B Baylin; J P Issa
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

8.  Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients.

Authors:  Giovanni Lanza; Roberta Gafà; Alessandra Santini; Iva Maestri; Laura Guerzoni; Luigi Cavazzini
Journal:  J Clin Oncol       Date:  2006-05-20       Impact factor: 44.544

9.  Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer.

Authors:  Virgínia Piñol; Antoni Castells; Montserrat Andreu; Sergi Castellví-Bel; Cristina Alenda; Xavier Llor; Rosa M Xicola; Francisco Rodríguez-Moranta; Artemio Payá; Rodrigo Jover; Xavier Bessa
Journal:  JAMA       Date:  2005-04-27       Impact factor: 56.272

10.  Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.

Authors:  Leonard B Saltz; Donna Niedzwiecki; Donna Hollis; Richard M Goldberg; Alexander Hantel; James P Thomas; Anthony L A Fields; Robert J Mayer
Journal:  J Clin Oncol       Date:  2007-08-10       Impact factor: 44.544
View more
  33 in total

1.  Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications.

Authors:  Frank A Sinicrope; Daniel J Sargent
Journal:  Clin Cancer Res       Date:  2012-02-02       Impact factor: 12.531

2.  Honokiol radiosensitizes colorectal cancer cells: enhanced activity in cells with mismatch repair defects.

Authors:  Zhiyun He; Dharmalingam Subramaniam; Satish Ramalingam; Animesh Dhar; Russell G Postier; Shahid Umar; Youcheng Zhang; Shrikant Anant
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-08-11       Impact factor: 4.052

3.  KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).

Authors:  Harry H Yoon; David Tougeron; Qian Shi; Steven R Alberts; Michelle R Mahoney; Garth D Nelson; Suresh G Nair; Stephen N Thibodeau; Richard M Goldberg; Daniel J Sargent; Frank A Sinicrope
Journal:  Clin Cancer Res       Date:  2014-03-31       Impact factor: 12.531

4.  Is microsatellite instability really a good prognostic factor of colorectal cancer?

Authors:  Ui Sup Shin; Sang Sik Cho; Sun Mi Moon; Sun Hoo Park; Sun Hee Jee; Eun-Joo Jung; Dae-Yong Hwang
Journal:  Ann Coloproctol       Date:  2014-02-28

5.  An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.

Authors:  Casey M Cosgrove; David L Tritchler; David E Cohn; David G Mutch; Craig M Rush; Heather A Lankes; William T Creasman; David S Miller; Nilsa C Ramirez; Melissa A Geller; Matthew A Powell; Floor J Backes; Lisa M Landrum; Cynthia Timmers; Adrian A Suarez; Richard J Zaino; Michael L Pearl; Paul A DiSilvestro; Shashikant B Lele; Paul J Goodfellow
Journal:  Gynecol Oncol       Date:  2017-11-11       Impact factor: 5.482

Review 6.  Identification of clinically relevant molecular subtypes in colorectal cancer: the dawning of a new era.

Authors:  Patrick G Johnston
Journal:  Oncologist       Date:  2014-04-09

7.  Microsatellite instability in colorectal cancer: from molecular oncogenic mechanisms to clinical implications.

Authors:  Aziz Zaanan; Katy Meunier; Fatiha Sangar; Jean-François Fléjou; Françoise Praz
Journal:  Cell Oncol (Dordr)       Date:  2011-04-12       Impact factor: 6.730

8.  Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.

Authors:  D Scott McMeekin; David L Tritchler; David E Cohn; David G Mutch; Heather A Lankes; Melissa A Geller; Matthew A Powell; Floor J Backes; Lisa M Landrum; Richard Zaino; Russell D Broaddus; Nilsa Ramirez; Feng Gao; Shamshad Ali; Kathleen M Darcy; Michael L Pearl; Paul A DiSilvestro; Shashikant B Lele; Paul J Goodfellow
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

Review 9.  Chemotherapy of MMR-deficient colorectal cancer.

Authors:  N Devaud; S Gallinger
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

10.  Prospective Evaluation of a 12-Gene Assay on Patient Treatment Decisions and Physician Confidence in Mismatch Repair Proficient Stage IIA Colon Cancer.

Authors:  Lindsay A Renfro; Nan Zhang; Margarita Lopatin; Calvin Chao; Steven R Alberts
Journal:  Clin Colorectal Cancer       Date:  2016-08-09       Impact factor: 4.481
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.